Helle Knudsen

The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D

H. Mouridsen, S. Møller, B. Ejlertsen, 2008, Acta oncologica.

retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.

Jens Overgaard, E. Balslev, K. Nielsen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.